GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius AG (OTCPK:SARTF) » Definitions » Loans Receivable

Sartorius AG (Sartorius AG) Loans Receivable : $0 Mil (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Sartorius AG Loans Receivable?

Sartorius AG's Loans Receivable for the quarter that ended in Mar. 2024 was $0 Mil.


Sartorius AG Loans Receivable Historical Data

The historical data trend for Sartorius AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius AG Loans Receivable Chart

Sartorius AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sartorius AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Sartorius AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Sartorius AG Loans Receivable Related Terms

Thank you for viewing the detailed overview of Sartorius AG's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Sartorius AG (Sartorius AG) Business Description

Address
Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.